Phio Pharmaceuticals Corp., a clinical-stage siRNA biopharmaceutical company, announced its participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series. The event, scheduled for June 30, 2025, will feature a presentation by CEO and Chairman Robert Bitterman, who will provide an update on the company's proprietary INTASYL® siRNA technology. The presentation will include progress reports on the ongoing clinical trial of the lead compound PH-762, which is being developed for the treatment of skin cancers. Positive interim safety and efficacy results have already been reported from the Phase 1b dose escalation clinical trial of PH-762. The presentation and live Q&A session can be accessed via the Renmark Financial Communications Inc. website, with a replay available post-event.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。